Philippines Business News API

{
    "totalArticles": 275940,
    "articles": [
        {
            "id": "446e079dabbb9a03ff0b55ff6c7f3788",
            "title": "JETOUR Partners with Middle East’s Premier Off-road Event LIWA, showcasing Travel+ strategy’s deep roots in the key market",
            "description": "Abu Dhabi, Dec. 25, 2025 (GLOBE NEWSWIRE) -- On December 20, during the Abu Dhabi LIWA International Festival, JETOUR Auto hosted its 2025 Global Fan Festival. As the Premier Partner of LIWA, JETOUR invited both international media and users together to join in the test drive session, the modified off-road vehicle experiences, and an off-road-themed music festival. Attendees at this event would have experienced the products on their own, and enjoyed the vibrant off-road lifestyle.",
            "content": "Abu Dhabi, Dec. 25, 2025 (GLOBE NEWSWIRE) -- On December 20, during the Abu Dhabi LIWA International Festival, JETOUR Auto hosted its 2025 Global Fan Festival. As the Premier Partner of LIWA, JETOUR invited both international media and users together... [3658 chars]",
            "url": "https://www.manilatimes.net/2025/12/25/tmt-newswire/globenewswire/jetour-partners-with-middle-easts-premier-off-road-event-liwa-showcasing-travel-strategys-deep-roots-in-the-key-market/2249517",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/25/879964.png",
            "publishedAt": "2025-12-25T10:08:18Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        },
        {
            "id": "e1f3898c709a7916efb9b9721cb491c0",
            "title": "China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval",
            "description": "TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer.The TABOSUN® and TYVYT® combination therapy significantly improved pathological complete response (pCR) rates and enabled most patients to avoid the burden of postoperative adjuvant chemotherapy.This therapy is the first and only dual-IO regimen approved globally for neoadjuvant treatment of colon cancer[i], filling a critical gap in neoadjuvant treatment of colon cancer and benefiting more patients with MSI-H/dMMR colon cancer.SAN FRANCISCO and SUZHOU, China, Dec. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for TABOSUN® (ipilimumab N01 injection; R&D Code: IBI310), the first domestic cytotoxic lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody (mAb), has been approved by China's National Medical Products Administration (NMPA), in combination with sintilimab as neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer. TABOSUN® (ipilimumab N01 injection) is the world's first approved CTLA-4 mAb for neoadjuvant treatment of colon cancer. Short-term neoadjuvant treatment with the ipilimumab N01 and sintilimab combination demonstrated a substantial improvement in pathological complete response, offering the potential to benefit a broader population of patients with MSI-H/dMMR colon cancer.",
            "content": "TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) ... [12312 chars]",
            "url": "https://www.manilatimes.net/2025/12/25/tmt-newswire/pr-newswire/chinas-first-domestic-anti-ctla-4-monoclonal-antibody-innovents-tabosun-ipilimumab-n01-injection-received-nmpa-approval/2249510",
            "image": "https://cdn4.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1920&q=100&f=webp&v=1",
            "publishedAt": "2025-12-25T09:14:11Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        },
        {
            "id": "55b8630b5ae076507c71f5156aea57c9",
            "title": "Asiana Airlines informs employees of personal data hack",
            "description": "Amid heightened concerns over personal data protection following Coupang’s large-scale customer data leak, Asiana Airlines has also disclosed a breach involving the personal information of about 10,000 employees.",
            "content": "Amid heightened concerns over personal data protection following Coupang’s large-scale customer data leak, Asiana Airlines has also disclosed a breach involving the personal information of about 10,000 employees.\nThe airline posted an emergency notic... [1242 chars]",
            "url": "https://koreajoongangdaily.joins.com/news/2025-12-25/national/socialAffairs/Asiana-Airlines-informs-employees-of-personal-data-hack/2486623",
            "image": "https://koreajoongangdaily.joins.com/data/photo/2025/12/25/c48d7fa4-9b16-47bb-ba31-77690a92a047.jpg",
            "publishedAt": "2025-12-25T08:59:12Z",
            "lang": "en",
            "source": {
                "id": "a342fbf30e609afd020e6397ba235b26",
                "name": "Korea JoongAng Daily",
                "url": "https://koreajoongangdaily.joins.com"
            }
        }
    ]
}